肺血管扩张药物治疗支气管肺发育不良相关性肺动脉高压的研究进展  

Progress on pulmonary vasodilator drugs in the treatment of bronchopulmonary dysplasia-associated pulmonary hypertension

作　　者：白晓婷 梅花[1] Bai Xiaoting;Mei Hua(Department of Neonatology,Afiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China;Department of Neonatology,The Third Hospital of BaoGang Group,Baotou 014010,China)

机构地区：[1]内蒙古医科大学附属医院新生儿科,呼和浩特010050 [2]包钢集团第三职工医院新生儿科,包头014010

出　　处：《中国小儿急救医学》2024年第5期358-362,共5页Chinese Pediatric Emergency Medicine

基　　金：内蒙古自治区自然科学基金项目(2020MS08034)。

摘　　要：支气管肺发育不良是极早产儿最常见的慢性肺疾病。部分重度支气管肺发育不良常合并肺动脉高压,以肺泡弥散性损害、肺血管重构异常为特征,继而导致肺血管阻力增加而发生右心衰竭,严重影响早产儿体格及神经发育。肺血管扩张药物可通过一氧化氮途径、内皮素途径及前列腺素途径降低肺动脉压力。本文就肺血管扩张药物在支气管肺发育不良相关性肺动脉高压治疗情况进行综述。Bronchopulmonary dysplasia is the most common chronic lung disease in very preterm infants.Some severe bronchopulmonary dysplasia is often combined with pulmonary hypertension,characterized by diffuse alveolar damage and abnormal pulmonary vascular remodeling,followed by right heart failure due to increased pulmonary vascular resistance.It seriously affects the physical and neurological development of preterm infants.Pulmonary vasodilator drugs can reduce pulmonary artery pressure through nitric oxide pathway,endothelin pathway and prostaglandin pathway.This review summarized the pulmonary vasodilator drugs in the treatment of pulmonary hypertension associated with bronchopulmonary dysplasia.

关 键 词：肺血管扩张药物 肺动脉高压 支气管肺发育不良 早产儿 

分 类 号：R725.6[医药卫生—儿科]